R9281

Rotigotine hydrochloride

≥98% (HPLC)

• Synonim(y): (−)-(S)-5,6,7,8-Tetrahydro-6-(propyl(2-(2-thienyl)ethyl)amino)-1-naphthol hydrochloride, (−)-N 0437, N 0923, Neupro, SPM 962
• Wzór empiryczny (zapis Hilla): C₁₉H₂₅NOS·HCl
• Numer CAS: 125572-93-2
• Masa cząsteczkowa: 351.93
• NACRES: NA.77
• PubChem Substance ID: 329824046
• UNSPSC Code: 12352200
• MDL number: MFCD00906149
• Assay: ≥98% (HPLC)
• Form: solid
• Storage condition: desiccated

Właściwości

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• storage condition: desiccated
• color: white to off-white
• solubility: DMSO: >10 mg/mL
• originator: UCB Inc.
• storage temp.: room temp
• SMILES string: Cl.CCCN(CCc1cccs1)[C@H]2CCc3c(O)cccc3C2
• InChI: 1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1
• InChI key: CEXBONHIOKGWNU-NTISSMGPSA-N

Opis

Biochem/physiol Actions

Rotigotine is a dopamine receptor agonist with preference for D₃ receptors over D₂ and D₁. As such, it is an effective anti-Parkinsonian agent.

Rotigotine is a dopamine receptor agonist with preference for D₃ receptors over D₂ and D₁. As such, it is an effective anti-Parkinsonian agent. Racemic rotigotine is about 50 times as potent as quinpirole, the gold standard D₂ agonist.

Rotigotine hydrochloride is a non-ergolinic D3/D2 and D1-dopamine agonist. It is appropriate for transdermal delivery through skin patches, that has the drug in a silicone-based adhesive matrix.

Features and Benefits

This compound was developed by UCB Inc.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 2
• flash_point_f: Not applicable
• flash_point_c: Not applicable